Sonnet BioTherapeutics Holdings, Inc. (SONN): Price and Financial Metrics

Sonnet BioTherapeutics Holdings, Inc. (SONN): $3.07

0.14 (-4.36%)

POWR Rating

Component Grades








Add SONN to Watchlist
Sign Up

Industry: Biotech




#192 of 359

in industry

SONN Price/Volume Stats

Current price $3.07 52-week high $66.00
Prev. close $3.21 52-week low $3.02
Day low $3.02 Volume 50,200
Day high $3.30 Avg. volume 103,926
50-day MA $6.33 Dividend yield N/A
200-day MA $13.05 Market Cap 5.38M

SONN Stock Price Chart Interactive Chart >


  • Growth is the dimension where SONN ranks best; there it ranks ahead of 95.23% of US stocks.
  • SONN's strongest trending metric is Value; it's been moving up over the last 179 days.
  • SONN's current lowest rank is in the Stability metric (where it is better than 2.31% of US stocks).

SONN Stock Summary

  • Revenue growth over the past 12 months for SONNET BIOTHERAPEUTICS HOLDINGS INC comes in at -77.52%, a number that bests merely 2.34% of the US stocks we're tracking.
  • In terms of volatility of its share price, SONN is more volatile than 98.57% of stocks we're observing.
  • SONNET BIOTHERAPEUTICS HOLDINGS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -370.25%, greater than the shareholder yield of only 1.69% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to SONNET BIOTHERAPEUTICS HOLDINGS INC, a group of peers worth examining would be BNTC, IKT, GNFT, BLPH, and BNOX.
  • Visit SONN's SEC page to see the company's official filings. To visit the company's web site, go to

SONN Valuation Summary

  • SONN's price/earnings ratio is -0.3; this is 101.1% lower than that of the median Healthcare stock.
  • Over the past 206 months, SONN's price/sales ratio has gone down 168.3.

Below are key valuation metrics over time for SONN.

Stock Date P/S P/B P/E EV/EBIT
SONN 2023-09-18 35.8 1.8 -0.3 0
SONN 2023-09-15 36.4 1.8 -0.3 0
SONN 2023-09-14 37.0 1.9 -0.3 0
SONN 2023-09-13 38.2 1.9 -0.3 0
SONN 2023-09-12 39.9 2.0 -0.3 0
SONN 2023-09-11 37.6 1.9 -0.3 0

SONN Growth Metrics

    Its year over year cash and equivalents growth rate is now at 102.34%.
  • Its 3 year price growth rate is now at -99.24%.
  • The 5 year cash and equivalents growth rate now stands at 97.71%.
SONN's revenue has moved down $25,369,187 over the prior 34 months.

The table below shows SONN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 0.257399 -25.5101 -29.063
2022-09-30 0.349943 -27.68728 -29.72184
2022-06-30 0.770816 -27.46372 -29.23857
2022-03-31 0.708745 -25.48387 -27.47709
2021-12-31 0.613425 -25.66291 -25.3077
2021-09-30 0.483626 -22.55224 -24.98396

SONN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SONN has a Quality Grade of D, ranking ahead of 9.63% of graded US stocks.
  • SONN's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • QGEN, ALNY, and RDUS are the stocks whose asset turnover ratios are most correlated with SONN.

The table below shows SONN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA 6.121
2021-03-30 0.000 NA 8.723
2020-12-31 0.492 0.045 -7.708
2020-09-30 0.000 NA -2.244
2020-06-30 0.549 0.025 -1.292
2020-03-31 0.683 0.039 -0.581

SONN Price Target

For more insight on analysts targets of SONN, see our SONN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.50 Average Broker Recommendation 1.25 (Strong Buy)

Sonnet BioTherapeutics Holdings, Inc. (SONN) Company Bio

Sonnet BioTherapeutics Holdings, Inc. operates as a clinical stage biotechnology company. The Company develops fully human albumin binding technology that helps the development of innovative targeted biologic drugs with enhanced single-or bi-specific mechanisms. Sonnet BioTherapeutics Holdings serves customers in the United States.

SONN Latest News Stream

Event/Time News Detail
Loading, please wait...

SONN Latest Social Stream

Loading social stream, please wait...

View Full SONN Social Stream

Latest SONN News From Around the Web

Below are the latest news stories about SONNET BIOTHERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate SONN as an investment opportunity.

Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced data from two radiolabeling studies that validate the tumor targeting attributes associated with albumin binding by the FHAB technology.

Yahoo | September 20, 2023

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market indicating that Sonnet has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

Yahoo | September 19, 2023

Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-22 reverse stock split of its outstanding common stock.

Yahoo | August 31, 2023

7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot Pole

There are some solid biotech stocks on the market.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | August 25, 2023

Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the IND for SB221 (NCT05756907), the Phase 1b/2a clinical trial of SON-1010(IL12-FHAB) in combination with Roche's anti-PD-L1 checkpoint inhibitor, atezolizumab, has been accepted, and the study can begin in the US for the treatment of PROC.

Yahoo | August 16, 2023

Read More 'SONN' Stories Here

SONN Price Returns

1-mo -51.88%
3-mo -79.32%
6-mo -58.09%
1-year -91.33%
3-year -99.59%
5-year -99.98%
YTD -87.87%
2022 -80.12%
2021 -81.48%
2020 -85.46%
2019 -54.26%
2018 -50.95%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!